Verrica Pharmaceuticals ( (VRCA) ) has released its Q3 earnings. Here is a breakdown of the information Verrica Pharmaceuticals presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company based in West Chester, PA, specializing in the development and commercialization of treatments for skin diseases. The company recently reported its earnings for the quarter ended September 30, 2025, highlighting significant financial developments and strategic milestones. Verrica Pharmaceuticals reported total revenue of $14.3 million for the third quarter of 2025, a substantial increase from a negative revenue position in the same period last year. This growth was driven by product revenue from YCANTH (VP-102) and milestone payments from its collaboration with Torii Pharmaceutical Co., Ltd. Despite the revenue growth, the company posted a net loss of $274,000 for the quarter, a significant improvement from the $22.9 million loss in the previous year. The company continues to face financial challenges, with a stockholders’ deficit of $17 million and cash and cash equivalents of $21.1 million as of September 30, 2025. Verrica Pharmaceuticals remains focused on securing additional capital to support its operations and meet its financial obligations. The management is optimistic about future growth, driven by strategic collaborations and the ongoing commercialization of its dermatological products.